Home » Stocks » NLTX

Neoleukin Therapeutics, Inc. (NLTX)

Stock Price: $10.40 USD -0.23 (-2.16%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 440.40M
Revenue (ttm) n/a
Net Income (ttm) -39.59M
Shares Out 42.35M
EPS (ttm) -2.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $10.40
Previous Close $10.63
Change ($) -0.23
Change (%) -2.16%
Day's Open 10.66
Day's Range 10.39 - 10.80
Day's Volume 232,229
52-Week Range 9.38 - 18.13

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SEATTLE, May 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein the...

2 weeks ago - GlobeNewsWire

- Entered clinical development with first patient dosed in Phase 1 Trial of NL-201 -

1 month ago - GlobeNewsWire

The FDA has removed the clinical hold related to Neoleukin Therapeutics Inc (NASDAQ: NLTX) investigational new drug application, to begin a Phase 1 program of its cancer immunotherapeutic candidate, NL-...

1 month ago - Benzinga

- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 -

2 months ago - GlobeNewsWire

SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...

3 months ago - GlobeNewsWire

SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

4 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - January 25, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). Su c...

4 months ago - Newsfile Corp

Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) -  Holzer & Holzer, LLC is investigating whether Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) ("Neoleukin" or the "Company") complied with federal se...

4 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). Su c...

4 months ago - Newsfile Corp

The company is experiencing regulatory headwinds.

5 months ago - The Motley Fool

Aquinox (NLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5 months ago - Zacks Investment Research

SEATTLE, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

5 months ago - GlobeNewsWire

Neoleukin Therapeutics is a biopharmaceutical company that creates next-gen immunotherapies targeting cancer, inflammation, and autoimmunity. Neoleukin's unique value-add is its specialization in novel-...

5 months ago - Seeking Alpha

SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

6 months ago - GlobeNewsWire

SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

6 months ago - GlobeNewsWire

SEATTLE, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

7 months ago - GlobeNewsWire

- NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation -

7 months ago - GlobeNewsWire

- NL-201 IND submission anticipated by year end 2020 -

7 months ago - GlobeNewsWire

- I ntranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection –

7 months ago - GlobeNewsWire

SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

7 months ago - GlobeNewsWire

SEATTLE, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

7 months ago - GlobeNewsWire

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: AZN, BIIB, MNTA, PRGO, RLMD, SNY, SUPN ...
8 months ago - Investopedia

SEATTLE, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...

9 months ago - GlobeNewsWire

Neoleukin (NLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

9 months ago - Zacks Investment Research

Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

SEATTLE, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein ...

10 months ago - GlobeNewsWire

SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein ...

10 months ago - GlobeNewsWire

SEATTLE, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...

10 months ago - GlobeNewsWire

The drug developer has an intriguing technology platform and expects to enter clinical trials before the end of 2020, but there are a few things investors cannot overlook.

10 months ago - The Motley Fool

Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.

Other stocks mentioned: DRRX, RLMD
11 months ago - The Motley Fool

Neoleukin (NLTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11 months ago - Zacks Investment Research

The development-stage drug company announced the pricing of a public offering of common stock.

11 months ago - The Motley Fool

SEATTLE, July 02, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protei...

11 months ago - GlobeNewsWire

SEATTLE, July 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...

11 months ago - GlobeNewsWire

Neoleukin Therapeutics (NLTX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

- NL-201 demonstrates durable antitumor activity in animal tumor models - - NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo - - Conditional activation of de novo p...

11 months ago - GlobeNewsWire

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: AMPH, CRON
1 year ago - Investopedia

SEATTLE, June 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein ...

1 year ago - GlobeNewsWire

Neoleukin (NLTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

SEATTLE, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protei...

1 year ago - GlobeNewsWire

Here are three stocks that have broken out of above resistance and are looking higher: Neoleukin Therapeutics, Inc.

Other stocks mentioned: SE, XPEL
1 year ago - Benzinga

SEATTLE, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protei...

1 year ago - GlobeNewsWire

SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protei...

1 year ago - GlobeNewsWire

SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...

1 year ago - GlobeNewsWire

About NLTX

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neole... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2003
Stock Exchange
NASDAQ
Ticker Symbol
NLTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for NLTX stock is "Strong Buy." The 12-month stock price forecast is 20.40, which is an increase of 96.15% from the latest price.

Price Target
$20.40
(96.15% upside)
Analyst Consensus: Strong Buy